FY2026 Earnings Forecast for BDRX Issued By Zacks Research

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) – Research analysts at Zacks Research issued their FY2026 earnings estimates for Biodexa Pharmaceuticals in a research note issued to investors on Monday, March 30th. Zacks Research analyst D. Bautz forecasts that the company will earn $0.00 per share for the year. The consensus estimate for Biodexa Pharmaceuticals’ current full-year earnings is ($1.25) per share. Zacks Research also issued estimates for Biodexa Pharmaceuticals’ FY2027 earnings at $0.00 EPS.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last issued its quarterly earnings data on Friday, March 27th. The company reported $0.70 EPS for the quarter.

A number of other equities research analysts have also issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen cut shares of Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Up 1.0%

Shares of NASDAQ BDRX opened at $0.62 on Wednesday. The company has a fifty day moving average price of $1.18 and a 200 day moving average price of $3.81. Biodexa Pharmaceuticals has a 1-year low of $0.60 and a 1-year high of $19.30.

Biodexa Pharmaceuticals’s stock is going to reverse split on the morning of Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, April 3rd.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC purchased a new stake in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned about 14.71% of Biodexa Pharmaceuticals at the end of the most recent reporting period. 17.51% of the stock is currently owned by institutional investors and hedge funds.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.